Identity
- Trade Name
- ihcDirect® E-Cadherin Ab Conjugate 5mL FDA UDI
- Generic Name
- E-cadherin epithelial marker IVD, kit, enzyme immunohistochemistry FDA UDI
- Device Name
- Clone R1005 FDA UDI
- Model / Reference
- H32036-R005 FDA UDI
- Description
- Clone R1005 FDA UDI
Identifiers
- Catalog Number
- K32036-005 FDA UDI
- Primary DI / UDI-DI
- 00850030934871 FDA UDI
- FDA Product Code
- NJT FDA UDI
- GMDN Term
- E-cadherin epithelial marker IVD, kit, enzyme immunohistochemistry FDA UDI
Classification
- Device Class
- Class I FDA UDI
- Regulation Number
- 864.1860 FDA UDI
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
No
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
No
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
Yes
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Dimensions & Sizes
- Size
- Total Volume — 5 Milliliter FDA UDI
Category: E-cadherin epithelial marker IVD, kit, enzyme immunohistochemistry
ihcDirect® E-Cadherin Ab Conjugate 5mL by Novodiax, Inc. — Class I — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as E-cadherin epithelial marker IVD, kit, enzyme immunohistochemistry.
- Q-STAIN® QSX-Enh-P E-Cad — NOVODIAX, INC. · Class I
- Q-STAIN® QSX-Enh-F E-Cad — NOVODIAX, INC. · Class I
- ihcDirect® E-Cadherin Ab Conjugate 15mL — NOVODIAX, INC. · Class I
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | Class I | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Novodiax, Inc.
Sources (1)
- FDA UDI 5ab5d89f-354a-4a07-b3e4-c3a95b97a5fa 37 fields · synced May 30, 2026